CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Biosynex SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Biosynex SA
22 Boulevard Sebastien Brant
Phone: +33 388787887p:+33 388787887 ILLKIRCH-GRAFFENSTADEN, 67400  France Ticker: ALBIOALBIO
Business Summary
Biosynex SA is a France-based company that specializes in the research, development and manufacture of in-vitro diagnostic kits aimed at health professionals. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). It operates through Fumouze Diagnostics and SR2B.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director LarryAbensur 6/24/2015 2/11/2005
Deputy Chief Executive Officer, Director ThomasLamy 6/24/2015 6/24/2015
Deputy Chief Executive Officer - Research and Business development, Administrator ThierryPaper 6/24/2015 2/11/2005
Director ElieFraenckel

Subsidiaries
Business Name Address City State/Province Country
Bigix Pharma Srl Via Orfanotrofio 10 Asti Italy
Chembio Diagnostics GmbH Schwarzschildstra?e 1 Berlin DE
Medkoncept A/S Mosehojvej 7A Charlottenlund Denmark
3 additional Subsidiary records available in full report.

Business Names
Business Name
ALBIO
AVALUN
Bigix Pharma Srl
6 additional Business Names available in full report.

General Information
Number of Employees: 560 (As of 6/30/2023)
Outstanding Shares: 9,996,354 (As of 6/30/2023)
Stock Exchange: EPA
Fax Number: +33 388787678


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 26, 2024